686
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Editorial

, MD, PhD

Dear Readers,

Welcome to the first edition of Ocular Immunology and Inflammation of 2021. As usual for this first edition of the year, I would like to reflect on what we have achieved over the last 12 months and then point to some highlights for the coming year.

In our series “Disease of the Year” we analyzed the “Inflammatory components of the Dry Eye” in 2020. Most of the planned reviews have been finalized or are currently under review. The Editorial Board for this consisted of Jennifer Craig (Auckland, New Zealand), Andrea Leonardi (Padua, Italy), Christophe Baudouin (Paris, France), Pedram Hamrah (Boston, USA), Stefano Barabino (Milan, Italy), and Friedrich Paulsen (Erlangen, Germany). I want to thank this group for all the work they have done.

For 2021 we have planned to leave defined ocular inflammatory disorders and to come back to “Diagnostics” with the topic of “Ocular Coherence Tomography.”

We are planning a series of approximately twelve topics. The Editorial Board will consist of Marion Munk (Bern, Switzerland), Ester Carreño Salas (Madrid, Spain), Alessandro Invernizzi (Milano, Italy), and Franceso Pichi (Abu Dhabi)

It seems that, probably due to reduced office work along the COVID-19-lockdowns, we saw a massive increase in submissions. This year, nearly 1000 manuscripts have been submitted to OII, a major increase from app. 600 in 2019. One volume of OII now consists of 8 issues. One issue of OII was nearly completely dedicated to COVID-19-induced ocular inflammation.

Such an increase of manuscripts to handle is only possible because the journal has supportive reviewing editors and reviewers. Thanks to all of you. An acknowledgment of reviewers by name can be found on OIIs page on Taylor & Francis Online. Of course, I also want to thank all contributors, and I encourage you to submit your best work to OII so that we can continue to provide our readers with the highest quality articles and reviews from the field of ocular immunology and inflammation.

Thank you for your continuing support and happy New Year!

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.